Franklin Lakes, New Jersey-based Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at a market cap of around $49 billion, the company operates through BD Medical, BD Life Sciences, and BD Interventional segments.

Companies worth $10 billion or more are generally labeled as “large-cap” stocks, and Becton, Dickinson and Company fits this criterion perfectly. The company has a strong global footprint and continues to drive innovation in areas like diabetes care, biosciences, and surgical solutions.

Becton, Dickinson and Company stock has declined 32.2% from its 52-week high of $251.99. Over the last three months, BDX stock has crumbled 23.8%, a steeper decline than the iShares U.S. Medical Devices ETF’s (IHI) 2% drop.

Longer term, shares of BDX have dipped 24.7% on a YTD basis, whereas IHI has returned 5.6%. Additionally, Becton, Dickinson and Company stock has slipped 28.3% over the past 52 weeks, notably lagging behind IHI’s 10.7% rise over the same time frame. 

Since February, the stock has been trading below its 50-day and 200-day moving averages.

Shares of Becton, Dickinson and Company tumbled 18.1% after the release of its mixed Q2 2025 results on May 1. The company reported revenue of $5.3 billion, up 4.5% year-over-year and slightly below Wall Street expectations of $5.4 billion. However, the BD Medical segment performed well, rising 12.7% to $2.6 billion, primarily driven by strong contributions from Advanced Perfusion Monitoring (APM). Its adjusted EPS came in at $3.35, marking a 5.7% increase from the prior-year quarter and surpassing analysts' estimates. 

Looking ahead to fiscal 2025, BDX raised its revenue outlook to a range of $21.8 billion to $21.9 billion. Nevertheless, it revised its adjusted EPS guidance downward to $14.06 - $14.34. 

In comparison, rival Intuitive Surgical, Inc. (ISRG) has surpassed BDX stock. ISRG stock is up 6.9% on a YTD basis and 37.2% over the past 52 weeks.

Despite BDX’s underperformance relative to its industry peers, analysts are moderately optimistic about its prospects. BDX has a consensus rating of “Moderate Buy” from the 17 analysts covering the stock. As of writing, the stock is trading below the mean price target of $213.71.